Meta Information
ID:quercetin-liposomal
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/dietary/high-fat-meal
Target name:
Meal Containing Fat
Severity:
moderate
Interaction type:
requirement
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin is a fat-soluble flavonoid, and its absorption from the gut is significantly increased when consumed with dietary fats.
Actionable advice:
Quercetin is best taken with a meal that includes healthy fats like olive oil, avocado, or nuts to improve absorption.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Compared to the fat-free trial, plasma quercetin maximum concentration (Cmax ), and area under curve (AUC0-24 h ) increased (p < 0.05) by 45 and 32%, respectively, during the high-fat trial.
Label source:
PubMed: Molecular nutrition & food research (2013)
Source url:
Exact phrase from label:
Irrespective of the chemical form applied, the bioavailability of quercetin was higher in the 17% fat diet compared with the 3% fat diet (P < 0.05).
Label source:
PubMed: The Journal of nutrition (2004)
Action type:
informational_none
Target id:
/class/immunosuppressants
Target name:
Calcineurin Inhibitors (e.g., Cyclosporine, Tacrolimus)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin inhibits CYP3A4 and P-glycoprotein, enzymes critical for metabolizing these drugs, which can dangerously increase their blood levels and risk of toxicity.
Actionable advice:
This should be strictly avoided if taking calcineurin inhibitors like cyclosporine or tacrolimus.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
In vitro studies from our laboratory suggest that short-term exposure with pure herbal agents such as hypericin, kaempferol and quercetin or extract of SJW resulted in higher uptake or influx of ritonavir and erythromycin. Hypericin, kaempferol and quercetin also caused a remarkable inhibition of cortisol metabolism with the percent intact cortisol values of 64.58%, 89.6% and 90.1%, respectively, during short-term in vitro experiments.
Label source:
PubMed: MDR- and CYP3A4-mediated drug-herbal interactions. (PMID 16442130)
Action type:
avoid
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets (e.g., Warfarin, Clopidogrel)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin may inhibit platelet aggregation, potentially adding to the effects of blood-thinning medications and increasing the risk of bleeding.
Actionable advice:
It is important to talk to a physician before use while taking any blood-thinning medications or with a bleeding disorder.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The affinity for this site is large and we found that quercetin may effectively displace warfarin from HSA.
Label source:
PubMed: Interactions between quercetin and warfarin for albumin binding: A new eye on food/drug interference. (PMID 19902529)
Action type:
informational_none
Target id:
/class/cyp3a4-substrates
Target name:
Drugs Metabolized by CYP3A4
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin is a moderate inhibitor of the CYP3A4 enzyme, which can slow the breakdown and increase the concentration of many common medications. Because the liposomal formulation substantially increases systemic exposure to this polyphenol, treat this enzyme-inhibition interaction as higher-stakes than for standard oral forms — particularly for narrow-therapeutic-index substrates.
Actionable advice:
Dosing should be separated, and it is worth watching for enhanced effects of CYP3A4-metabolized drugs; for narrow-therapeutic-index substrates (e.g. certain immunosuppressants, some statins, some anticoagulants), this combination should be cleared with a prescriber.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Although QR did not show any significant effect on CYP1A2 and CYP2E1, it exhibited a strong inhibitory effect against CYP2D6 and a moderate effect against CYP2C19 and CYP3A4.
Label source:
PubMed: Studying the Inhibitory Effect of Quercetin and Thymoquinone on Human Cytochrome P450 Enzyme Activities. (PMID 29491651)
Action type:
adjust_with_prescriber
Target id:
/class/cyp2c9-substrates
Target name:
Drugs Metabolized by CYP2C9 (e.g., Warfarin, some NSAIDs)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin can inhibit the CYP2C9 enzyme, potentially increasing the levels and effects of drugs metabolized through this pathway. Because the liposomal formulation substantially increases systemic exposure to this polyphenol, treat this enzyme-inhibition interaction as higher-stakes than for standard oral forms — particularly for narrow-therapeutic-index substrates.
Actionable advice:
This is best used with caution, and it is important to talk to a healthcare professional when taking medications metabolized by CYP2C9.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
These results indicated that the herb-drug interaction between quercetin and losartan might occur when they are co-administered in rats, quercetin could increase the systemic exposure of losartan and decrease the plasma concentration of EXP3174, possibly by inhibiting the activity of P-gp or CYP450 enzyme.
Label source:
PubMed: Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. (PMID 29768080)
Action type:
informational_none
Target id:
/class/p-glycoprotein-substrates
Target name:
P-glycoprotein Substrates (e.g., Digoxin, Fexofenadine)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin inhibits the P-glycoprotein (P-gp) efflux pump, which can increase the absorption and blood levels of certain drugs, enhancing their effects and side effects.
Actionable advice:
Concurrent use with P-gp substrate drugs is best avoided unless cleared by a doctor.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Some components (e.g., bergamottin and quercetin) from grapefruit juice were reported to modulate Pgp activity. Many of these herbal constituents, in particular flavonoids, were reported to modulate Pgp by directly interacting with the vicinal ATP-binding site, the steroid-binding site, or the substrate-binding site.
Label source:
PubMed: Herbal modulation of P-glycoprotein. (PMID 15072439)
Action type:
avoid
Target id:
/procedure/major-surgery
Target name:
Scheduled Surgery
Severity:
moderate
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
336
Hours after target:
null
Description:
Due to its potential antiplatelet (blood-thinning) effects, quercetin may increase the risk of bleeding during and after surgical procedures.
Actionable advice:
Quercetin should be discontinued at least 2 weeks prior to any scheduled surgery.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/intervention/iron-bisglycinate
Target name:
Iron Supplements
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Quercetin is an iron chelator, meaning it can bind to iron in the digestive tract and significantly reduce its absorption.
Actionable advice:
Doses of quercetin and iron supplements should be separated by at least 2 hours.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Quercetin binds iron between its 3-hydroxyl and 4-carbonyl groups and methylation of the 3-hydroxyl group negated both the increase in apical uptake and the inhibition of basolateral iron release, suggesting that the acute effects of quercetin on iron transport were due to iron chelation.
Label source:
PubMed: Quercetin inhibits intestinal iron absorption and ferroportin transporter expression in vivo and in vitro. (PMID 25058155)
Action type:
separate
Target id:
/class/chemotherapy-radiation
Target name:
Chemotherapy & Radiation
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The antioxidant properties of quercetin could theoretically interfere with the effectiveness of cancer therapies that rely on oxidative stress to destroy malignant cells.
Actionable advice:
This should be strictly avoided during active cancer treatment unless specifically directed by an oncologist.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Doxorubicin (DOX) is a widely used chemotherapeutic agent, but its clinical application is limited by dose-dependent cardiotoxicity linked to oxidative stress, mitochondrial dysfunction, and apoptosis. Quercetin (QU), a natural flavonoid with potent antioxidant properties, provides cardioprotection but exhibits poor bioavailability.
Label source:
PubMed: Cardiac-Targeted Quercetin-Loaded PLGA Nanoparticles Attenuate Doxorubicin-Induced Cardiotoxicity via Nrf2/HO-1 Pathway Activation in Mice. (PMID 41423342)
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
There is insufficient safety data to establish the effects of quercetin supplementation during pregnancy.
Actionable advice:
Quercetin supplements should be avoided during pregnancy due to a lack of safety information.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
Not enough is known about the use of quercetin during pregnancy and breast-feeding.
Label source:
Anecdotal: RxList
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is not known if quercetin passes into breast milk or what its effects might be on a nursing infant.
Actionable advice:
Quercetin supplements should be avoided while breastfeeding due to a lack of safety information.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
Quercetin passes into breast milk. Tell your health care provider if you are breastfeeding or plan to breastfeed.
Label source:
Anecdotal: WebMD
Action type:
avoid
Target id:
/intervention/dasatinib
Target name:
Dasatinib (Senolytic Therapy)
Severity:
major
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin is intentionally combined with Dasatinib in specific protocols to act as a senolytic agent, synergistically helping to clear senescent cells.
Actionable advice:
It should be taken at the same time as Dasatinib only when used as part of a medically supervised senolytic protocol.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Dasatinib was clastogenic when tested in vitro in Chinese hamster ovary cells, with and
without metabolic activation.
Label source:
Action type:
informational_none
Target id:
/intervention/zinc
Target name:
Zinc
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin acts as a zinc ionophore, a molecule that helps transport zinc ions across cell membranes, potentially enhancing zinc's intracellular activity.
Actionable advice:
It is generally best taken at the same time as zinc to potentially increase cellular zinc levels.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
FTIR spectral data revealed that Q acts as a bidentate ligand (chelating ligand) through carbonyl C(4) = O oxygen and phenolic C(3)-OH oxygen in conjugation with Zn.
Label source:
PubMed: Quercetin/Zinc complex and stem cells: A new drug therapy to ameliorate glycometabolic control and pulmonary dysfunction in diabetes mellitus: Structural characterization and genetic studies. (PMID 33661932)
Action type:
informational_none
Target id:
/intervention/vitamin-c
Target name:
Vitamin C
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Vitamin C can help regenerate oxidized quercetin back to its active form, potentially enhancing its antioxidant capacity and bioavailability.
Actionable advice:
Consider taking with Vitamin C to support quercetin's antioxidant activity.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy.
Label source:
PubMed: Frontiers in immunology (2020)
Source url:
Exact phrase from label:
The results show that ascorbic acid can protect flavonoids from oxidative degradation, and reveal antioxidant synergies between ascorbic acid and the compounds.
Label source:
PubMed: Redox report : communications in free radical research (2004)
Source url:
Exact phrase from label:
Vitamins E, C and polyphenols (flavonoids and non-flavonoids) are major natural antioxidants capable of preventing damage generated by oxidative stress. Here we show the capacity of these antioxidants to form non-covalent association within lipid bilayers close to the membrane/cytosol interface. Antioxidant regeneration is significantly enhanced in these complexes.
Label source:
PubMed: Chemical communications (Cambridge, England) (2015)
Action type:
informational_none
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin may have mild blood pressure-lowering effects, which could be additive with antihypertensive drugs, potentially leading to hypotension.
Actionable advice:
It is a good idea to check blood pressure if combining with blood pressure medication.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Further studies are necessary to investigate the clinical relevance of these results and the possibility of quercetin application as an add-on to antihypertensive therapy.
Label source:
PubMed: Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PMID 27405810)
Action type:
monitor
Target id:
/class/chelating-antibiotics
Target name:
Quinolone Antibiotics (e.g., Ciprofloxacin)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin may interfere with the action of quinolone antibiotics through several proposed mechanisms, including enzyme inhibition.
Actionable advice:
Quercetin and quinolone antibiotics are best separated rather than taken at the same time.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The results showed that 64-256 µg/mL quercetin significantly increased the accumulation of ciprofloxacin in antibiotic-resistant bacteria, inhibited the efflux of ciprofloxacin by 2-10-fold downregulation of the expression of the efflux pump genes norA, norB, norC, and mepA, and modulated the protein expression profile of S. aureus.
Label source:
PubMed: Foodborne pathogens and disease (2025)
Source url:
Exact phrase from label:
In this study, we describe five flavonoids, quercetin, luteolin, kaempferol, baicalein, and commercially available CID12261165, that show similar antimicrobial activity against fluoroquinolone-resistant S. aureus.
Label source:
PubMed: Scientific reports (2023)
Action type:
avoid
Target id:
/intervention/bromelain
Target name:
Bromelain
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The enzyme bromelain is thought to enhance the absorption of quercetin in the small intestine, though evidence is limited.
Actionable advice:
Can be taken with bromelain to potentially improve absorption.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
On the contrary, bromelain could possibly increase plasma exposure of the cited drugs due to its known muco-permeation enhancing effect.
Label source:
PubMed: Development and validation of UPLC-MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction. (PMID 34325247)
Action type:
informational_none
Target id:
/intervention/fisetin
Target name:
Fisetin
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
As both are flavonoid senolytics, taking them together may produce additive or synergistic effects on cellular senescence and antioxidant pathways. However, findings of a human clinical study suggests that adding fisetin to dasatinib (D) and quercetin (Q) may mitigate the effect of D+Q.
Actionable advice:
Can be taken with fisetin for potentially complementary effects.However, it is unclear whether there is added benefit to taking fisetin with quercetin
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
Since both have senolytic properties, combining them can help your body address senescent cells, which are like worn-out batteries that can slow down your system.
Label source:
Anecdotal: Life Extension
Action type:
informational_none
Target id:
/dietary/hot-foods-beverages
Target name:
Hot Foods or Beverages
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Liposomal quercetin relies on a heat-sensitive phospholipid bilayer to protect and deliver its payload. Stirring it into a hot beverage (coffee, tea, soup) can melt or rupture the liposomes, destroying the enhanced-absorption advantage that is the entire point of the liposomal form.
Actionable advice:
Liposomal quercetin should not be added to hot drinks or food. It should be taken with cool or room-temperature liquid to keep the liposomes intact.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Mechanism / liposome thermal stability
Exact phrase from label:
Phospholipid liposomal delivery systems are thermally labile and lose bilayer integrity when exposed to hot liquids, negating the absorption advantage of the liposomal format.
Label source:
Mechanistic inference
Action type:
avoid
Derived From
quercetin
Provenance Note
Interactions duplicated from 'quercetin'. Liposomal formulation; same interactions. | liposomal-bioavailability CYP severity escalation 2026-07-02